dept header
Directory | Contact
Mission of the Division

The Division of Thoracic Surgery was established at NYU School of Medicine in September 2005 with the arrival of Dr. Harvey Pass, Director of the Division and Chief of Thoracic Oncology.

As part of the NYU Department of Cardiothoracic Surgery, we take pride in diagnosing and treating both benign and malignant neoplasms (tissue growths), as well as providing management of other disorders of the lungs, esophagus, mediastinum and the chest wall.

The NYU Thoracic Oncology Program's multidisciplinary approach unites the disciplines of medical oncology, surgery, radiation therapy, pulmonary medicine, radiology and pathology. Through weekly evidence-based discussions, cases of new and existing patients are reviewed by members of these disciplines, resulting in multifaceted expert opinions that allow us to tailor our care to the individual needs of our patients. These meetings are held in three locations - Tisch, Bellevue, and the Manhattan Veterans Affairs Hospitals - in order to provide the greatest number of patients with the newest developments in treatment available through NYU Medical Center.

Our minimally invasive surgery program incorporates video-assisted and "open chest" techniques along with new methods for post-operative pain relief. Procedures include:

  • video-assisted thoracoscopy for the chest

  • video-assisted laparoscopy for the abdomen

  • video-assisted procedures on benign lesions of the esophagus and lungs

  • minimally invasive esophagectomy and pulmonary resection

We also place a unique emphasis on the treatment of pleural mesothelioma using a multimodal approach.

A key part of providing compassionate clinical care is research. That's why we are committed to state-of-the-art surgical management and to developing novel treatment strategies using clinical trials. We also use the resources at the New York Thoracic Surgery Laboratory housed at Bellevue Hospital to launch investigations at the gene or protein level. Through studies like these we make clinically relevant "bench to bedside" discoveries in early detection and develop targeted therapies.

We also provide the newest in pioneering treatments, including: